Login to Your Account



Other News To Note


Friday, September 27, 2013
• Agenus Inc., of Lexington, Mass., entered a nonexclusive license agreement with Vaxlogic LLC, a subsidiary of Boca-Raton, Fla.-based Pharmlogic LLC, for the use of QS-21 Stimulon adjuvant in the development of select addiction, allergy and respiratory disease vaccine candidates.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription